ValuEngine downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report released on Wednesday.
Several other research analysts also recently commented on OMER. Zacks Investment Research raised Omeros from a hold rating to a strong-buy rating and set a $22.00 price objective for the company in a research note on Thursday, October 19th. Maxim Group set a $24.00 price objective on Omeros and gave the company a buy rating in a research note on Friday, October 20th. Cowen downgraded Omeros from an outperform rating to a market perform rating in a research note on Thursday, November 2nd. HC Wainwright initiated coverage on Omeros in a research note on Wednesday, November 8th. They issued a buy rating and a $30.00 price objective for the company. Finally, Wedbush reissued an outperform rating and issued a $47.00 price objective on shares of Omeros in a research note on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $30.38.
Omeros (NASDAQ:OMER) opened at $11.25 on Wednesday. Omeros has a 52 week low of $10.52 and a 52 week high of $27.09. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99. The company has a market capitalization of $655.25, a price-to-earnings ratio of -8.79 and a beta of 3.31.
TRADEMARK VIOLATION NOTICE: This story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/02/15/omeros-omer-cut-to-sell-at-valuengine.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.